Terns Pharmaceuticals CFO sells $110,000 in company stock By Investing.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Chief Financial Officer Mark J. Vignola recently engaged in transactions involving the company’s common stock, according to a new SEC filing. On September 10, Vignola sold 10,000 shares of Terns Pharmaceuticals at an average price of $11.00 per share, totaling $110,000.

The transactions were executed under a Rule 10b5-1 trading plan, which Vignola had previously adopted on March 18, 2024. This plan allows company insiders to set up a predetermined schedule for buying and selling stock at a time when they are not in possession of material non-public information, providing a defense against claims of insider trading.

On the same day, the CFO also acquired 10,000 shares of the company’s common stock at $5.36 per share, which amounted to a total transaction value of $53,600. This acquisition was part of an employee stock option exercise, as outlined in the footnotes of the SEC filing. The footnotes also detail the vesting schedule of the stock options, indicating that 25% of the shares subject to the option vested on the first anniversary from the Vesting Commencement Date, with additional shares vesting monthly over four years.

Following the reported transactions, Vignola’s ownership in Terns Pharmaceuticals stands at 91,940 shares of common stock directly owned, and 55,000 shares underlying vested stock options.

Investors and followers of Terns Pharmaceuticals often monitor insider buying and selling as it can provide insights into the company’s performance and the confidence level of its executives. However, it is important to note that these transactions do not necessarily indicate future performance and may be subject to personal financial needs or strategies of the individual executive.

Terns Pharmaceuticals, based in Foster City, California, is in the pharmaceutical preparations industry and focuses on developing innovative treatments. The company’s financial year ends on December 31.

In other recent news, Terns Pharmaceuticals reported positive results from its Phase 1 trial for TERN-601, a potential obesity treatment, with Jefferies and TD Cowen maintaining their positive ratings on the company’s shares. The trial results showed promising outcomes, leading Jefferies to increase its price target for Terns Pharmaceuticals to $30.00 from the previous $22.00. Furthermore, Terns Pharmaceuticals launched a $125 million stock offering, led by Jefferies and TD Cowen, to fund the development of key product candidates such as TERN-701 and TERN-601.

In addition, the company appointed Elona Kogan as its new chief legal officer, further strengthening its strategic development. Terns Pharmaceuticals is also making progress in its ongoing Phase 1 study of TERN-701, with interim findings suggesting the drug can be administered once daily with or without food.

Mizuho Securities maintained its Outperform rating on Terns Pharmaceuticals, citing strong enthusiasm for the company’s drug, TERN-701, a potential treatment for chronic myeloid leukemia. These are among the recent developments at Terns Pharmaceuticals, which continues to advance its strategic objectives and deliver on its mission.

InvestingPro Insights

As Terns Pharmaceuticals Inc. (NASDAQ:TERN) navigates the pharmaceutical preparations industry, its financial maneuvers have caught the eye of investors. The company’s Chief Financial Officer’s recent transactions in company stock provide a glimpse into insider confidence, a factor often scrutinized by market participants. To add context to these developments, a look at some real-time metrics and InvestingPro Tips can provide a broader understanding of Terns Pharmaceuticals’ current financial health and market performance.

InvestingPro Data shows that Terns Pharmaceuticals holds a market capitalization of $670.64 million, reflecting the company’s valuation in the market. Despite a challenging profitability outlook, as indicated by a negative P/E ratio of -7.42 and an adjusted P/E ratio for the last twelve months as of Q2 2024 at -7.84, the company has demonstrated robust price performance with significant returns over various periods, including an 80.8% return over the last year and a 46.53% year-to-date price total return.

Two InvestingPro Tips that are particularly relevant to investors are:

• The company holds more cash than debt on its balance sheet, suggesting a solid liquidity position that could be reassuring for investors considering the recent insider transactions.
• Analysts have revised their earnings estimates downwards for the upcoming period, which may influence the company’s stock price and should be factored into investment decisions.

These insights are just a snapshot of the comprehensive analysis available on InvestingPro, which lists over 12 additional InvestingPro Tips for Terns Pharmaceuticals. For a deeper dive into the company’s performance and expert projections, visit https://www.investing.com/pro/TERN.

As the CFO’s recent stock transactions are digested by the market, Terns Pharmaceuticals’ financial metrics and InvestingPro Tips can help investors gauge the company’s standing and make more informed decisions. With its strong return over various time frames and a solid liquidity position, Terns Pharmaceuticals remains a company to watch in the pharmaceutical preparations sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.